** Shares of Neurotech International NTI.AX rise 6.5% to A$0.033
** Stock set for strongest session since March 18, if current gains hold
** European Commission gives "orphan drug" designation to biopharmaceutical firm's NTI64 drug aimed at treating Rett Syndrome, a neurodevelopmental disorder that affects motor and communication skills
** European Commission grants "orphan drug" designation to promote medicine development for rare diseases affecting no more than 5 in 10,000 people in the European Union
** Co says "orphan" status gives it a range of incentives including 10-year market exclusivity, reduced regulatory fees and access to EU research funding
** Stock down 40% YTD, including current session's moves
(Reporting by Nikita Maria Jino in Bengaluru)
((Nikita.Jino@thomsonreuters.com;))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。